UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totaling 201 shares, a decline of 82.7% from the April 15th total of 1,164 shares. Based on an average trading volume of 107,071 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Ratings Changes

A number of brokerages have recently commented on UCBJY. Zacks Research raised UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 14th. Wolfe Research raised shares of UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Three research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, UCB presently has a consensus rating of “Strong Buy”.

UCB Price Performance

Shares of OTCMKTS UCBJY opened at $140.97 on Thursday. UCB has a twelve month low of $84.94 and a twelve month high of $168.76. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The firm has a 50-day moving average of $146.78 and a two-hundred day moving average of $145.23.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.